Drug Trial Radar · NCT04690192
CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jan 1, 2021
Primary completion
Dec 30, 2023
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Juventas Cell Therapy Ltd.
- First posted
- Dec 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to explore the safety and efficacy of CNCT19 (a second-generation anti-CD19 CAR T-cell using 4-1BB as co-stimulatory domain provided by Juventas, Tianjin, China) infusion following ASCT in patients with relapsed or refractory B-cell lymphoma.
Conditions
- Large B-cell Lymphoma
Interventions
CNCT19Biological
2×10\^6/kg, infused in a single-dose on day +2, +3 or +4 following stem-cell infusion
Gemcitabine InjectionDrug
600mg/m2/h, infused for 3 hours with loading bolus of 75mg/m2, day -7, -3,
busulfanDrug
105mg/m2, day -7 until -5,
Melphalan InjectionDrug
60mg/m2, day -3, -2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants experiencing adverse eventsTime frame: from the first day of high-dose chemotherapy until 2 years post CNCT19 infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.